Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TDP1 | Q9NUW8 | 3/20 | 0.57 |
| ▸ | RECQL | P46063 | 3/20 | 0.57 |
| ▸ | PTGS1 | P23219 | 3/20 | 0.49 |
| ▸ | PTGS2 | P35354 | 3/20 | 0.49 |
| ▸ | CYP19A1 | P11511 | 3/20 | 0.49 |
| ▸ | TYR | P14679 | 1/20 | 0.49 |
| ▸ | CYP3A4 | P08684 | 4/20 | 0.42 |
| ▸ | MEN1 | O00255 | 4/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.42 |
| ▸ | SYNJ2 | O15056 | 1/20 | 0.42 |
| ▸ | BCL2 | P10415 | 1/20 | 0.40 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.38 |
| ▸ | CA12 | O43570 | 2/20 | 0.38 |
| ▸ | AMY1A | P0DUB6 | 2/20 | 0.38 |
| ▸ | CA4 | P22748 | 2/20 | 0.38 |
| ▸ | CA7 | P43166 | 2/20 | 0.38 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.38 |
| ▸ | SLCO2B1 | O94956 | 1/20 | 0.38 |
| ▸ | TTR | P02766 | 1/20 | 0.38 |
| ▸ | ESR1 | P03372 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL677662 | 1.00 | TDP1 (0.57) | TDP1RECQLPTGS1PTGS2CYP19A1 | |
| SCHEMBL28035038 | 0.87 | RECQL (0.49) | TDP1RECQLPTGS1PTGS2CYP19A1 | |
| SCHEMBL349722 | 0.84 | CYP3A4 (0.52) | TDP1RECQLPTGS1PTGS2CYP19A1 | |
| SCHEMBL28030289 | 0.84 | TDP1 (0.55) | TDP1RECQLPTGS1PTGS2CYP19A1 | |
| SCHEMBL3487578 | 0.84 | CYP3A4 (0.52) | TDP1RECQLPTGS1PTGS2CYP19A1 | |
| SCHEMBL7809366 | 0.83 | CYP19A1 (0.45) | TDP1RECQLPTGS1PTGS2CYP19A1 | |
| SCHEMBL29282180 | 0.83 | CYP19A1 (0.45) | TDP1RECQLPTGS1PTGS2CYP19A1 | |
| SCHEMBL28888148 | 0.83 | BCL2 (0.42) | TDP1RECQLPTGS1PTGS2CYP19A1 | |
| SCHEMBL27796498 | 0.83 | BCL2 (0.42) | TDP1RECQLPTGS1PTGS2CYP19A1 | |
| SCHEMBL28616927 | 0.81 | RECQL (0.44) | TDP1RECQLPTGS1PTGS2CYP19A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6737439-B2 | ACTIVE CANCER CHEMOPREVENTATIVE AND TREATING AGENTS IN MAMMALS, INCLUDING HUMANS | THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS | 2004-05-18 | — | — | US | claimed |
| US-20030125377-A1 | Aromatase inhibitors from Broussonetia papyrifera | BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS THE | 2003-07-03 | — | — | US | claimed |
| US-6737439-B2 | ACTIVE CANCER CHEMOPREVENTATIVE AND TREATING AGENTS IN MAMMALS, INCLUDING HUMANS | THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS | 2004-05-18 | — | — | US | disclosed |
| US-20030125377-A1 | Aromatase inhibitors from Broussonetia papyrifera | BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS THE | 2003-07-03 | — | — | US | disclosed |
| WO-2003013554-A2 | AROMATASE INHIBITORS FROM BROUSSONETIA PAPYRIFERA | THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS (US) | 2003-02-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030125377-A1 | Aromatase inhibitors from Broussonetia papyrifera | CYP19A1, HSD17B11, CYP17A1 | TDP1 659/4885RECQL 1275/4885PTGS1 35/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.